Matinas BioPharma Holdings Inc Provides an Update and Overview for the Clinical Development of MAT2203
Llamada en conferencia Matinas BioPharma Holdings Inc
Matinas BioPharma Holdings Inc Conference call or earnings call will be held on 27-jun-2017 via an 800 number (toll-free). During the earnings conference call's session Matinas BioPharma Holdings Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Matinas BioPharma Holdings Inc for this information
Schedule a teleconference with QCONF and get 5 free calls with our conference service.
We are a clinical-stage biopharmaceutical company focused on identifying and developing safe and effective broad spectrum therapeutics for the treatment of serious and life-threatening infections. We are developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections. On January 29, 2015, we completed the acquisition of Aquarius Biotechnologies Inc., (referred to as the "Aquarius Merger" throughout this document), a New Jersey-based, early-stage pharmaceutical company focused on the development of differentiated and orally delivered therapeutics based on a proprietary, lipid crystal drug delivery platform called "cochleate delivery technology". Our proprietary cochleate delivery technology platform, licensed from Rutgers University on an exclusive worldwide basis, is designed specifically for the targeted and safe delivery of pharmaceuticals directly to the site of infection or inflammation.Leer más Llamada en conferencia